News
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to treat patients with earlier stage cancer, Novartis said.
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease, following the U.S. Food and Drug Administration's expanded approval of the treatment ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.
The Food and Drug Administration expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease, drugmaker Novartis said Tuesday ...
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.
“The FDA approval of Kisqali for this early breast cancer population, including those with NO [hasn't spread to nearby lymph nodes] disease, is a pivotal moment in improving our approach to care ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.
The FDA expanded approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease. The decision will free up access to the medication for tens of ...
The FDA expanded the approval of Kisqali, a drug for metastatic breast cancer, to also treat patients with earlier stages of the disease.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results